Literature DB >> 29971829

Index serum hyaluronic acid independently and accurately predicts mortality in patients with liver disease.

N Plevris1, R Sinha2, A W Hay3, N McDonald4, J N Plevris2, P C Hayes5.   

Abstract

BACKGROUND: Hyaluronic acid is a recognised noninvasive marker of liver fibrosis. However, its prognostic ability has not been extensively studied. AIMS: To investigate the ability of an index serum hyaluronic acid measurement to independently predict transplant-free survival in patients with liver disease of varying aetiology and severity.
METHODS: This was a retrospective single-centre cohort study. Serum hyaluronic acid was measured at the discretion of the attending clinicians, in patients attending the liver clinic, to assess disease severity. Patients with a hyaluronic acid measurement between 1995 and 2010 were identified. Patient characteristics at the point of hyaluronic acid measurement were recorded from medical records. Follow-up was from date of index hyaluronic acid measurement to date of death, date of transplant or censor date (July 01, 2015). Primary outcomes were all-cause and liver-related mortality. Kaplan-Meier analysis was used to compare survival in 3 patient groups with hyaluronic acid levels of <100 μg/L, 100-300 μg/L and >300 μg/L. Survival models were constructed using Cox proportional hazard and prediction accuracy was assessed by Harrell's C-statistic.
RESULTS: Five hundred and eighty nine patients fulfilled inclusion criteria. Median follow-up was 5.6 years (range 0.1-19.7). Transplant-free survival was significantly different between patients with hyaluronic acid <100 μg/L, 100-300 μg/L and >300 μg/L for liver-related as well as all-cause mortality (P < 0.001). Hyaluronic acid level was an independent predictor of survival (liver-related: HR 1.39, 95% CI 1.20-1.60, P < 0.001; all-cause: HR 1.04, 95% CI 1.02-1.06, P = 0.001). The liver-related prediction accuracy of hyaluronic acid was 0.74 (Standard error 0.03).
CONCLUSION: Index hyaluronic acid measurement can accurately and independently predict liver-related and all-cause mortality in patients with liver disease.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29971829     DOI: 10.1111/apt.14897

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

1.  Liver impairment in critical illness and sepsis: the dawn of new biomarkers?

Authors:  Martin Kluge; Frank Tacke
Journal:  Ann Transl Med       Date:  2019-12

2.  Fc gamma RIIb expression levels in human liver sinusoidal endothelial cells during progression of non-alcoholic fatty liver disease.

Authors:  Tomoko Ishikawa; Hiroshi Yokoyama; Tomokazu Matsuura; Yoko Fujiwara
Journal:  PLoS One       Date:  2019-01-29       Impact factor: 3.240

3.  Model for liver hardness using two-dimensional shear wave elastography, durometer, and preoperative biomarkers.

Authors:  Bing-Jie Ju; Ming Jin; Yang Tian; Xiang Zhen; De-Xing Kong; Wei-Lin Wang; Sheng Yan
Journal:  World J Gastrointest Surg       Date:  2021-02-27

4.  Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study.

Authors:  Sheila M Grecian; Stela McLachlan; Jonathan A Fallowfield; Peter C Hayes; Indra Neil Guha; Joanne R Morling; Stephen Glancy; Rachel M Williamson; Rebecca M Reynolds; Brian M Frier; Nicola N Zammitt; Jackie F Price; Mark W J Strachan
Journal:  Obes Sci Pract       Date:  2021-05-06

5.  Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis.

Authors:  Hao-Jie Zhong; Huan-Huan Sun; Lan-Feng Xue; Eileen M McGowan; Yu Chen
Journal:  World J Gastroenterol       Date:  2019-01-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.